XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER LEFT
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
-0.80 · CENTER
ML v2 (DistilBERT)
0.282 · RIGHT
Ensemble
-0.259 · CENTER LEFT
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg 0.002
1,107 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our […]
Read full article at Financial Post ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
pending
Jun 15, 2026